Document:

Agreement Regarding Conversion Of Promissory Note Prakash

 Exhibit 10.85 
  
 AGREEMENT REGARDING CONVERSION OF PROMISSORY NOTE 
  
 THIS AGREEMENT dated as of July 29, 2005, by and between Biovest International, Inc. a Delaware corporation (“Biovest”) and
Anaka Prakash who is the Holder of Certain Convertible Promissory Note(s) convertible into Biovest Common Stock (hereinafter “Holder”), is as follows: 
  
 WHEREAS Biovest and Holder understand and acknowledge that Biovest Common Stock is in the process of being listed for sale on the NASD Over
the Counter-Bulletin Board for public trading; and 
  
 WHEREAS it is in the
interest of both Biovest and Holder that the number of shares of Common Stock of Biovest that are subject to contingent issuance under Warrants and Convertible Notes (“Overhang”) be consistent with comparable public companies in order to
be able to sustain a good market value accurately reflecting the company’s actual value and the potential of its future growth and success; and 
  
 WHEREAS both Biovest and Holder acknowledge and agree that the existence of large outstanding Overhang creates uncertainty and a potentially destabilizing influence on
the market value of Biovest Common Stock, which tends to prevent the maintenance of a trading price accurately reflecting the value of Biovest; 
  
 NOW THEREFORE, for good and valuable consideration, receipt of which is hereby mutually acknowledged, the parties hereby agree as follows: 
  
 1. Subject to the terms contained herein, Holder hereby irrevocably covenants and agrees to
convert the entire outstanding balance (Principal and all accrued interest) due on Holder’s Promissory Notes as particularly identified on the attached Exhibit A into Common Stock of Biovest at $0.75 per share. The foregoing provision replaces
and supersedes all provisions regarding conversion rights into Biovest Common Stock contained in Holder’s Convertible Promissory Note(s). 
  
 2. Holder hereby covenants and agrees to convert the entire balance, including accrued interest on each of the Convertible Promissory Notes set forth on Exhibit A within
30 days of the date of this Agreement contingent upon and subject only to the following: 
 A. Biovest’s commencement of trading on the Over the
Counter-Bulletin Board ; 
 B. Holder’s previously having converted this Note(s) into Accentia Common Stock in accordance with the terms of the
Convertible Note(s). 
  
 3. Biovest agrees to issue to Holder and Holder
agrees to accept from Biovest in full and complete satisfaction of all rights and obligations pursuant to the Convertible Promissory Note(s) identified in Exhibit A hereto the number of shares of Biovest Common Stock set forth on Schedule B hereto,
which shares shall be fully-paid and non-assessable. 

 4. Biovest and Holder acknowledge and agree that either the Biovest Common Stock (or, in the event that Holder elects to
convert into Accentia Common Stock as set forth in paragraph 2(b), the Accentia Common Stock) issued pursuant to this Agreement may bear a restrictive legend stating that the shares are not registered securities under the Securities Act of 1933, as
amended, or any state securities laws, unless Holder qualifies for an exemption from said restrictions. 
  
 5. Representations: 
  
 A. Holder acknowledges
and represents that Holder has had access to all reports filed with the SEC by Biovest; 
  
 B. Holder is an “Accredited Investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended, (ii) Holder has the financial ability to bear the economic risk of Holder’s investment as
contemplated by this Agreement, and (iii) Holder was given the opportunity to ask questions to (and received satisfactory answers from) Biovest regarding the terms and conditions of this Agreement; 
  
 C. Other than as specifically set forth herein, there have been no representations or
warranties made by either party to the other. 
  
 6. Holder and Biovest hereby
agree to submit any dispute that may arise pursuant to this agreement to arbitration under the auspices of the American Arbitration Association Rules of Commercial Arbitration, to be venued in Tampa, FL. This agreement is subject to final approval
by the Board of Directors of Biovest. 
  

							
	Biovest International, Inc.	 	Holder
				
	By:	 	 /s/  James McNulty

	 	Signature	 	 /s/  Anaka Prakash

	Name:	 	James McNulty	 	Name:	 	Anaka Prakash
	Title:	 	CFO	 	Date:	 	9/20/05
	Date:	 	9/30/05	 	 	 	 

 EXHIBIT A 
  

1. Promissory Note dated October 11, 2001 in the Principal Amount of $75,000. 
  
 Schedule B 
  
 Biovest shall issue a total of 108,960 shares of Common Stock, fully-paid and non-assessable, in full conversion and satisfaction of all sums due and obligations owed
pursuant to the Note set forth above.Agreement Regarding Conversion Of Promissory Note Tsakopoulos

 Exhibit 10.86 
  
 AGREEMENT REGARDING CONVERSION OF PROMISSORY NOTE 
  
 THIS AGREEMENT dated as of July 28, 2005, by and between Biovest International, Inc. a Delaware corporation (“Biovest”) and
Angelo Tsakopoulos who is the Holder of Certain Convertible Promissory Note(s) convertible into Biovest Common Stock (hereinafter “Holder”), is as follows: 
  
 WHEREAS Biovest and Holder understand and acknowledge that Biovest Common Stock is in the process of being listed for sale on the NASD Over
the Counter-Bulletin Board for public trading; and 
  
 WHEREAS it is in the
interest of both Biovest and Holder that the number of shares of Common Stock of Biovest that are subject to contingent issuance under Warrants and Convertible Notes (“Overhang”) be consistent with comparable public companies in order to
be able to sustain a good market value accurately reflecting the company’s actual value and the potential of its future growth and success; and 
  
 WHEREAS both Biovest and Holder acknowledge and agree that the existence of large outstanding Overhang creates uncertainty and a potentially destabilizing
influence on the market value of Biovest Common Stock, which tends to prevent the maintenance of a trading price accurately reflecting the value of Biovest; 
  
 NOW THEREFORE, for good and valuable consideration, receipt of which is hereby mutually acknowledged, the parties hereby agree as follows: 
  
 1. Subject to the terms contained herein, Holder hereby irrevocably covenants and agrees to
convert the entire outstanding balance (Principal and all accrued interest) due on Holder’s Promissory Notes as particularly identified on the attached Exhibit A into Common Stock of Biovest at $0.60 per share. The foregoing provision replaces
and supersedes all provisions regarding conversion rights into Biovest Common Stock contained in Holder’s Convertible Promissory Note(s). 
  
 2. Holder hereby covenants and agrees to convert the entire balance, including accrued interest on each of the Convertible Promissory Notes set forth on Exhibit A within
30 days of the date of this Agreement contingent upon and subject only to the following: 
 A. Biovest’s commencement of trading on the Over the
Counter-Bulletin Board ; 
 B. Holder’s previously having converted these Notes into Accentia Common Stock in accordance with the terms of the
Convertible Note(s). 
  
 3. Biovest agrees to issue to Holder and Holder agrees to
accept from Biovest in full and complete satisfaction of all rights and obligations pursuant to the Convertible Promissory Note(s) identified in Exhibit A hereto the number of shares of Biovest Common Stock set forth on Schedule B hereto, which
shares shall be fully-paid and non-assessable. 

 4. Biovest and Holder acknowledge and agree that either the Biovest Common Stock (or, in the event that Holder elects to
convert into Accentia Common Stock as set forth in paragraph 2(b), the Accentia Common Stock) issued pursuant to this Agreement shall bear a restrictive legend stating that the shares are not registered securities under the Securities Act of 1933,
as amended, or any state securities laws. 
  
 5. Representations: 
  
 A. Holder acknowledges and represents that Holder has had access to all reports filed with
the SEC by Biovest; 
  
 B. Holder is an “Accredited Investor” as defined
in Regulation D promulgated under the Securities Act of 1933, as amended, (ii) Holder has the financial ability to bear the economic risk of Holder’s investment as contemplated by this Agreement, and (iii) Holder was given the
opportunity to ask questions to (and received satisfactory answers from) Biovest regarding the terms and conditions of this Agreement; 
  
 C. Other than as specifically set forth herein, there have been no representations or warranties made by either party to the other. 
  
 6. Holder and Biovest hereby agree to submit any dispute that may arise pursuant to this
agreement to arbitration under the auspices of the American Arbitration Association Rules of Commercial Arbitration, to be venued in Tampa, FL. This agreement is subject to final approval by the Board of Directors of Biovest. 
  

							
	Biovest International, Inc.	 	Holder
				
	By:	 	 /s/ James McNulty

	 	Signature	 	 /s/ Angelo Tsakopoulos

	Name:	 	James McNulty	 	Name:	 	Angelo Tsakopoulos
	Title:	 	CFO	 	Date:	 	7/29/05
	Date:	 	9/30/05	 	 	 	 

 EXHIBIT A 
  

1. Promissory Note dated March 7, 2003 in the Principal Amount of $250,000. 
  
 Schedule B 
  
 Biovest shall issue a total of 764,634 shares of Common Stock, fully-paid and non-assessable, in full conversion and satisfaction of all sums due and obligations owed
pursuant to the Notes set forth above.Clarification Agreement

 Exhibit 10.87 
  
 CLARIFICATION AND MODIFICATION OF 
 AGREEMENT REGARDING CONVERSION OF PROMISSORY NOTE 
  
 THIS CLARIFICATION AND MODIFICATION OF PROMISSORY NOTE hereby amends and supplements that certain AGREEMENT REGARDING CONVERSION OF PROMISSORY NOTE (the “Agreement”) dated as of July 29, 2005, by and between Biovest
International, Inc., a Delaware corporation (“Biovest”), and the undersigned (“Holder”) as follows: 
  
 Paragraph 1 of the Agreement is hereby modified by adding the following sentence to the end of said paragraph: “The conversion described in this paragraph will occur
at the time and upon the conditions set forth in paragraph 2 below, and such conversion will occur automatically and without any further action on the part of the Holder or Biovest.” 
  
 Paragraph 2 of the Agreement is hereby deleted and replaced with the following: “The automatic conversion of the principal and all
accrued interest under the Convertible Promissory Notes pursuant to Paragraph 1 above shall occur on the date which is the earlier of (a) thirty (30) days after the closing of the initial underwritten public offering of Accentia
Biopharmaceuticals, Inc. or (b) December 1, 2005. Notwithstanding the foregoing, such conversion shall be conditioned on the following: (i) Biovest’s common stock must be quoted on the OTC Bulletin Board as of the date of
conversion, and (ii) the Holder shall not have previously converted such Convertible Promissory Notes into common stock of Accentia Biopharmaceuticals, Inc pursuant to the terms of such notes. Upon such conversion, all principal and accrued but
unpaid interest through the date of conversion shall be deemed to have been automatically and irrevocably paid in full.” 
  
 All other terms of the Agreement shall continue in full force and effect. This Clarification and Modification shall be deemed to be effective as of September 27,
2005. 
  

							
	BIOVEST INTERNATIONAL, INC.	 	HOLDER
				
	By:	 	  

	 	Signature:	 	  

	 Name:
 Title:
	 	 	 	Name:	 	  

	 	 	 	 	 
				
	 	 	 	 	Signature:	 	  

				
	 	 	 	 	Name:	 	  

			
	 ACCENTIA BIOPHARMACEUTICALS, INC.
 (assenting
to both the Agreement and this Clarification and Modification)
	 	 	 	 
				
	By:	 	  

	 	 	 	 
	Name:	 	 	 	 	 	 
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]